These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35203756)

  • 21. Whole genome sequencing for the molecular characterization of carbapenem-resistant Klebsiella pneumoniae strains isolated at the Italian ASST Fatebenefratelli Sacco Hospital, 2012-2014.
    Rimoldi SG; Gentile B; Pagani C; Di Gregorio A; Anselmo A; Palozzi AM; Fortunato A; Pittiglio V; Ridolfo AL; Gismondo MR; Rizzardini G; Lista F
    BMC Infect Dis; 2017 Oct; 17(1):666. PubMed ID: 29017452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.
    Lim TP; Cai Y; Hong Y; Chan EC; Suranthran S; Teo JQ; Lee WH; Tan TY; Hsu LY; Koh TH; Tan TT; Kwa AL
    Antimicrob Agents Chemother; 2015 May; 59(5):2515-24. PubMed ID: 25691628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Tigecycline Resistance Among Tigecycline Non-susceptible
    Moghimi M; Haeili M; Mohajjel Shoja H
    Front Microbiol; 2021; 12():702006. PubMed ID: 34421858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insight into Antibiotic Synergy Combinations for Eliminating Colistin Heteroresistant
    Rajakani SG; Xavier BB; Sey A; Mariem EB; Lammens C; Goossens H; Glupczynski Y; Malhotra-Kumar S
    Genes (Basel); 2023 Jul; 14(7):. PubMed ID: 37510330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-Resistant
    Mantzana P; Protonotariou E; Kassomenaki A; Meletis G; Tychala A; Keskilidou E; Arhonti M; Katsanou C; Daviti A; Vasilaki O; Kagkalou G; Skoura L
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro synergy and postantibiotic effect of colistin combinations with meropenem and vancomycin against Enterobacteriaceae with multiple carbapenem resistance mechanisms.
    Bedenić B; Car H; Slačanac D; Sviben M; Čačić M; Lukić-Grlić A; Benčić A; Šijak D; Tripković M; Beader N
    J Infect Chemother; 2018 Dec; 24(12):1016-1019. PubMed ID: 30006247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic analysis of a pan-resistant Klebsiella pneumoniae sequence type 11 identified in Japan in 2016.
    Nishida S; Ono Y
    Int J Antimicrob Agents; 2020 Apr; 55(4):105854. PubMed ID: 31770626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of polymyxin B in combination with meropenem, amikacin and gentamicin against Klebsiella pneumoniae clinical isolates co-harbouring aminoglycoside-modifying enzymes, bla
    Firmo EF; Oliveira Júnior JB; Scavuzzi AML; Alves LC; Brayner FA; Veras DL; Lopes ACS
    J Glob Antimicrob Resist; 2020 Sep; 22():511-514. PubMed ID: 32344124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E.coli and Klebsiella pneumoniae by checkerboard method.
    Dhandapani S; Sistla S; Gunalan A; Manoharan M; Sugumar M; Sastry AS
    Indian J Med Microbiol; 2021 Jan; 39(1):6-10. PubMed ID: 33516606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae.
    Crémieux AC; Dinh A; Nordmann P; Mouton W; Tattevin P; Ghout I; Jayol A; Aimer O; Gatin L; Verdier MC; Saleh-Mghir A; Laurent F
    J Antimicrob Chemother; 2019 Sep; 74(9):2666-2675. PubMed ID: 31263884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro synergistic activity of fosfomycin in combination with other antimicrobial agents against carbapenem-resistant Klebsiella pneumoniae isolated from patients in a hospital in Thailand.
    Chukamnerd A; Pomwised R; Paing Phoo MT; Terbtothakun P; Hortiwakul T; Charoenmak B; Chusri S
    J Infect Chemother; 2021 Mar; 27(3):507-514. PubMed ID: 33221181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance.
    Laishram S; Anandan S; Devi BY; Elakkiya M; Priyanka B; Bhuvaneshwari T; Peter JV; Subramani K; Balaji V
    J Chemother; 2016 Aug; 28(4):297-303. PubMed ID: 27461479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.
    Souli M; Galani I; Boukovalas S; Gourgoulis MG; Chryssouli Z; Kanellakopoulou K; Panagea T; Giamarellou H
    Antimicrob Agents Chemother; 2011 May; 55(5):2395-7. PubMed ID: 21321144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic characterization of XDR Klebsiella pneumoniae ST147 co-resistant to carbapenem and colistin - The first report in India.
    Dey S; Gaur M; Sahoo RK; Das A; Jain B; Pati S; Subudhi E
    J Glob Antimicrob Resist; 2020 Sep; 22():54-56. PubMed ID: 32470551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates.
    Stein C; Makarewicz O; Bohnert JA; Pfeifer Y; Kesselmeier M; Hagel S; Pletz MW
    PLoS One; 2015; 10(6):e0126479. PubMed ID: 26067824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae.
    Tian Y; Zhang Q; Wen L; Chen J
    Microbiol Spectr; 2021 Oct; 9(2):e0015221. PubMed ID: 34704782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin.
    Tang HJ; Lai CC; Chen CC; Zhang CC; Weng TC; Chiu YH; Toh HS; Chiang SR; Yu WL; Ko WC; Chuang YC
    J Microbiol Immunol Infect; 2019 Apr; 52(2):273-281. PubMed ID: 27133391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emergence of OXA-48- and NDM-1-positive Klebsiella pneumoniae in Riyadh, Saudi Arabia.
    Shibl A; Al-Agamy M; Memish Z; Senok A; Khader SA; Assiri A
    Int J Infect Dis; 2013 Dec; 17(12):e1130-3. PubMed ID: 24021566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.